 |
2 Diseases |  |
27 Trials |
|
27 Trials |  |
1089 News |  |
| «12...45678910111213141516» |
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Where does digoxin sit on this slide with 15% ⬇️ RRR in combined endpoint and NNT 8? Not to mention cost efficacy 🆚 Vericiguat and Omecantiv mecarbil. (Twitter) - Dec 7, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
The benefits of vericiguat seem modified by BNP values. The lower the BNP value, the higher the benefit. Vericiguat seems not to be efficacious if NT-ProBNP is over 5000 (or 8000) @CVCTForum #CVCT2020 (Twitter) - Dec 6, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
On to the bext sedsion of @CVCTForum #CVCT2020 Now new drugs for heart failure: vericiguat and omecamtiv mecarbil @CVCTForum #CVCT2020 @hvanspall @FaiezZANNAD @rachkataria (Twitter) - Dec 6, 2020
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Review, Journal: Heart failure in the last year: progress and perspective. (Pubmed Central) - Dec 6, 2020
Second, vericiguat, an oral soluble guanylate cyclase stimulator, reduced the composite endpoint of cardiovascular death or HF hospitalization vs. placebo (HR 0.90; 95% CI 0.82-0.98; P = 0.02)...A better phenotyping of patients with HF would be helpful for prognostic stratification and treatment selection. Further aspects, such as the use of devices, treatment of arrhythmias, and percutaneous treatment of valvular heart disease in patients with HF, are also discussed and reviewed in this article.
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
💟Join me, @Barbara_Casadei @jteerlinkmd @JavedButler1 #PArmstrong #IPinea #FMalik #DDemets to discuss role of #Vericiguat & #OmecamtivMecarbil in #HFrEF 💟From RCT evidence to mechanisms, we’ve got you covered 💟Sun 930 EST 💟Free https://t.co/fk7EwZYQCL #CVCT2020 @CVCTForum (Twitter) - Dec 5, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
Clinical: New(ish) and niche medications for #heartfailure: ivabradine, vericiguat, omacamtiv mecabril. @DrNancySweitzer #HFPatientDay @HFSA. (Twitter) - Dec 5, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
#ESCardioAsia @escardio @TJ_Yeo @lamcardio What an ending slide! Truly a revolution in HFrEF treatment! 📍ARNIs 📍SGLT inhibitors 📍Vericiguat 📍Omecamtiv Looking forward to future studies for additive effects in CV reduction with these new drugs! (Twitter) - Dec 5, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: JACC: Heart Failure Editor's Update Read the min focus on Cardiogenic shock, PAC catheters back: time for Escape-2, personalized medical approach with Vericiguat, and the hall of fame inductee ,Mike Bristow, and lessons from farm to lab to patients. Enjoy! https://t.co/KPQiqv2y4v (Twitter) - Nov 20, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
What is vericiguat's relationship to #NTproBNP and outcomes? Check out this study by Dr. @JustinEzekowitz in #JACCHF. https://t.co/8cAutsGZao @coconnormd @texhern (Twitter) - Nov 18, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
Clinical: After the four pillars of GDMT, if the patient still requires additional medication (but preLVAD-transplant), what will you enter first? Vericiguat or omecamtiv mecarbil? Or, based on GALACTIC subanalysis of better response is LVEF<28%, OM if LVEF<28% vericiguat if LVEF>28%? (Twitter) - Nov 16, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
💯, that’s where I see its utility. After the pillars and after assessing suitability for add-on therapy such as Vericiguat/Ivabridine. PS. you are lucky to have an outstanding mentor. And you’ve done him proud!!! Few things more special than the mentor-mentee relationship! (Twitter) - Nov 14, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, HEOR: Yes! @jteerlinkmd has been awesome for me, that’s big COI. I see omecamtiv (depending on cost effectiveness) filling a need for sicker patients with lower BP (vericiguat SBP cutoff 100 mmHg) or worse renal function who cannot tolerate #HFrEF pillars or hospitalized despite them. (Twitter) - Nov 14, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: On balance, #SHIFT (Ivab) & #VICTORIA (vericiguat) showed greater risk reduction in the same composite endpoint as #GALACTIC (omecamtiv) w/ smaller RCT population; similar or shorter f/u period; lower baseline CV deaths (ie less power). Smaller NNT for these drugs than omecamtiv. (Twitter) - Nov 14, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: #Galactic was optimally designed to show Tx effect & the event rates confirm this. The PIs are to be congratulated. That said, I’d place Omecamtiv below Ivabridine & Vericiguat in hierarchy of HFrEF drugs. Not foundational Tx, may have utility in select pts dep on $ / access (Twitter) - Nov 14, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer
Retrospective data, Review, Journal: Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. (Pubmed Central) - Nov 14, 2020
Further aspects, such as the use of devices, treatment of arrhythmias, and percutaneous treatment of valvular heart disease in patients with HF, are also discussed and reviewed in this article. The use of vericiguat and riociguat in conjunction with standard HF therapy, shows no benefit in terms of decreasing HF-related hospitalizations or mortality.
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Third talk by @lamcardio about the role of soluble GC inhibitors. ⭐️ novel mechanism ⭐️ Even in #SGLT2i studies in HF, residual risk remains ⭐️ in VICTORIA, vericiguat reduced risk of composite outcome (HFH or CV death) (Twitter) - Nov 14, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Clinical data: New publication in @JAMACardio from @lamcardio and co-authors: Clinical Outcomes and Response to #Vericiguat According to Index HF Event - Insights From the #VICTORIATrial. @JustinEzekowitz @texhern @coconnormd (Twitter) - Nov 14, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Top tier #GDMTWorks for HFrEF remains ARNI, BB, MRA, SGLT2I. These are first line. Supplementary / alternative tools: barostim, CCM, vericiguat, ivabridine, OM, CardioMEMS, HeartLogic. We need implementation science. @gcfmd @DrNasrien @RyanTedfordMD @robmentz @NMHheartdoc (Twitter) - Nov 14, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Obviously yes this drug is not #ARNI nor #SGLT2i. The results of the trial suggest that this is a drug for severe #HF and also hypotensive #HF (not able to tolerate ARNI/ACE/BB). I think next algorithm will put it together with #Vericiguat ad a 3rd line therapy @TomLuscher (Twitter) - Nov 14, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: First step is maybe to reach full doses of major classes (BB, SRAi, MRA), introduce Sacu/Val in validated indications, then Vericiguat in severe HF patients. I m just wondering how many remaining pts will benefit from this Tx. (Twitter) - Nov 13, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Do you think this changes practice or would u need to see this benefit on top of SGLT2i? Reminiscent of small effect of vericiguat - I wonder if you have to find a subgroup with a stronger response... (Twitter) - Nov 13, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Marginal 1’ end point, no benefit in CVD death, HF hospitalizations, symptoms (KCCQ), NTproBNP. Not the holy grail that was hoped for. ? to be used in very low EF & symptomatic pts ? competing with vericiguat here? Both niche populations (Twitter) - Nov 13, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
La reducción del endpoint primario fue de tan solo un 8%. Me parece que por ahora será una opción terapéutica para pacientes refractarios a la terapia cuádruple, tal cual el vericiguat (Twitter) - Nov 13, 2020
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Journal, HEOR: Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. (Pubmed Central) - Nov 12, 2020
P2
Among patients with HFpEF and recent decompensation, 24-week treatment with vericiguat at either 15-mg/d or 10-mg/d dosages compared with placebo did not improve the physical limitation score of the KCCQ. ClinicalTrials.gov Identifier: NCT03547583.
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, P1 data, PK/PD data, Journal: Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. (Pubmed Central) - Oct 31, 2020
In general, vericiguat was well tolerated. These results supported further clinical evaluation of vericiguat QD in patients with heart failure.
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Journal: Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. (Pubmed Central) - Oct 30, 2020
VICTORIA comprises a broadly generalizable high-risk population of three unique clinical strata of worsening chronic HFrEF despite very good HF therapy. VICTORIA will establish the role of vericiguat, a soluble guanylate cyclase stimulator, in HFrEF.
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Happening Now. Live Journal Club unpacking #VICTORIA trial analysis by @JustinEzekowitz @coconnormd #PaulArmstrong NT-proBNP & #Vericiguat Response in #HFrEF Paper in @JACCJournals #JACCHF https://t.co/SzNX65V0Df Editorial by @JonWCunningham & @PSJhund https://t.co/IJFpzC2oSN https://t.co/KmvI7DNWIL (Twitter) - Oct 30, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Clinical data: TODAY at noon! #JACCHF is hosting a virtual journal club featuring discussion on "N-Terminal Pro-B-Type Natriuretic Peptide & Clinical Outcomes: Vericiguat #HeartFailure With Reduced Ejection Fraction Study." Register here: https://t.co/A5S0JZLEfx @ShashankSinhaMD @mvaduganathan (Twitter) - Oct 30, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Clinical data: Tomorrow at noon, #JACCHF is hosting a virtual journal club featuring discussion on "N-Terminal Pro-B-Type Natriuretic Peptide & Clinical Outcomes: Vericiguat #HeartFailure With Reduced Ejection Fraction Study." Register: https://t.co/A5S0JZLEfx @ShashankSinhaMD @mvaduganathan (Twitter) - Oct 29, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Don’t miss #Jacchf journal club-important paper on Vericiguat effect by NTproBNP quartiles- could this play a role in future use? @mpsotka @DrNasrien @coconnormd @JJheart_doc @DukeHFDoc @yaleHFdoc @mrchrtfaildoc @LindenfeldJoann @JonWCunningham (Twitter) - Oct 29, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Clinical data: Serial NT-proBNP and Clinical Outcomes in the VICTORIA trial presented at #CCCongress by @JustinEzekowitz during the Canadian and intl perspectives on LBCTs session. #vericiguat @AdriaanVoors @CindyWesterhout @WendimAlemayehu @JavedButler1 @coconnormd @texhern @lamcardio (Twitter) - Oct 23, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
The expanding compendium of #GDMT discussed by @DktrV benefits of Vericiguat and Omecamtiv. Given the data would you wait try these therapies or move@onto VAD/HTx? Access and Implementation will need to be key. #CCCongress @SCC_CCS (Twitter) - Oct 22, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD), praliciguat (IW-1973) / Cyclerion
Novel vericiguat and praliciguat bombed phase II for HFpEF but @KatAAClark and @ericjvelazquez say there may still be hope https://t.co/z1mZ4v9ZqD @MedPageCardio @medpagetoday @gcfmd @MinnowWalsh @NMHheartdoc (Twitter) - Oct 21, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: In this RCT, vericiguat oral—a guanylate cyclase stimulator which directly generates cGMP—did not improve functional outcomes at 24 wks vs placebo in pts w #HFpEF and recent heart failure decompensation https://t.co/yS7PbQSLPI @pwa_2000 @lamcardio @JavedButler1 #VisualAbstract (Twitter) - Oct 20, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer
Clinical, Reimbursement: In HFrEF pts w/ eGFR<30, would you consider cGC stimulator besides BB & hydral/ISDN? Best #GDMT for bad kidneys? Can’t prescribe vericiguat. Insurance requires ⬆️PVR for Riociguat. (Twitter) - Oct 17, 2020
- | vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Journal: Vericiguat in Heart Failure with Reduced Ejection Fraction. (Pubmed Central) - Oct 15, 2020
VICTORIA will establish the role of vericiguat, a soluble guanylate cyclase stimulator, in HFrEF. No abstract available
- | vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Journal: Vericiguat in Heart Failure with Reduced Ejection Fraction. (Pubmed Central) - Oct 15, 2020
No abstract available No abstract available
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. (Pubmed Central) - Oct 15, 2020
No abstract available No abstract available
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial 👇🏻 https://t.co/cfFzGfUWo2 @ESC_Journals @CVR_TomaszGuzik @AnastasiaSMihai @AndrewJSauer @HFA_President @mvaduganathan @lamcardio @hvanspall @ShelleyZieroth @BiykemB @FH_Verbrugge (Twitter) - Oct 10, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
I’ll take the 25% reduction in all caus MR and HFH in the Dig trial any day over omecantiv mecarbil or Vericiguat for that matter. (Twitter) - Oct 8, 2020
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: In @JACCJournals #JACCHF today @JustinEzekowitz & VICTORIA team show greater efficacy of vericiguat in lower NT-proBNP subgroups In the editorial, @PSJhund and I compare to ARNI and SGLT2i trials, and speculate about mechanism https://t.co/2WITm45at1 (Twitter) - Oct 7, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Also - editorial by @PSJhund & @JonWCunningham on an article led by @JustinEzekowitz from the VICTORIA trial examining the effect of vericiguat according to NTproBNP levels - Vericiguat in HFrEF With High Natriuretic Peptides A Case of Too Little, Too Late?https://t.co/FdD54kB8mt (Twitter) - Oct 7, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
ICYMI: “The importance of this study is that it allows us now to examine the effects of vericiguat relative to other therapies #HFSA2020 @HFSA #cardiotwitter @JustinEzekowitz @UAlberta @JJheart_doc @MGHHeartHealth https://t.co/UE5p4ro9Ww (Twitter) - Oct 7, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
ICYMI: “The importance of this study is that it allows us now to examine the effects of vericiguat relative to other therapies #HFSA2020 @HFSA #cardiotwitter @JustinEzekowitz @UAlberta @JJheart_doc @MGHHeartHealth https://t.co/UE5p4r6z4Y (Twitter) - Oct 6, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
An analysis of the VICTORIA trail showed that the benefits of vericiguat in HFrEF was consistent across various background therapies for HFrEF #HFSA2020 @HFSA #cardiotwitter @JustinEzekowitz @UAlberta @JJheart_doc @MGHHeartHealth https://t.co/UE5p4r6z4Y (Twitter) - Oct 6, 2020
- vericiguat (BAY 1021189) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
[VIRTUAL] EMERGING OPTIONS (OR POLYPHARMACY) FOR RECENT HOSPITALIZATION FOR HEART FAILURE ON OMT (Simulive + Live Q&A) - Oct 4, 2020 - Abstract #CCCCanada2020CCC_Canada_230;
Omecamtiv mecarbil iii. .ATTR- Positive PYP scan-test in evolution
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
In his presentation from the #VICTORIAtrial session, Dr. Javed Butler (@JavedButler1) discussed where #vericiguat fits in the contemporary standard of care management of #HF. #HFSA2020 (Twitter) - Oct 4, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Presenting new insights from the #VICTORIAtrial, Dr. Adrian Hernandez (@texhern) highlighted how prognostic modelling in patients with #HFrEF and recent decompensation can help us understand the likelihood of unfavorable outcomes. #vericiguat #HFSA2020 (Twitter) - Oct 4, 2020
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Presenting new findings from the #VICTORIAtrial, Dr. Robert Mentz (@robmentz) examined what can be learned about the important group of patients who have recurrent events after initial hospitalization for worsening #HF. #vericiguat #HFSA2020 (Twitter) - Oct 4, 2020
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Presenting insights from the #VICTORIAtrial, Dr. Justin Ezekowitz (@JustinEzekowitz) explored how to best define an optimal standard of background medical care. #vericiguat #HFSA2020 (Twitter) - Oct 4, 2020